Cover [Abstract]
Statement [Table]
Statement [Table]
Class of Stock [Axis]
Class of Stock [Domain]
Common Stock
Common stock warrants
Statement [Line Items]
Statement
Debt
Document Type
Document Type
Document Quarterly Report
Document Period End Date
Document Period End Date
Document Transition Report
Entity File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Postal Zip Code
City Area Code
Local Phone Number
Title of 12(b) Security
Trading Symbol
Security Exchange Name
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Document Fiscal Year Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
CONDENSED CONSOLIDATED BALANCE SHEETS
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock
Assets [Abstract]
ASSETS
Assets, Current [Abstract]
Current assets:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Prepaid Expense and Other Assets, Current
Total prepaid expense and other current assets
Prepaid expense and other current assets
Assets, Current
Total current assets
Other Assets, Noncurrent
Other assets
Assets
Total assets
Liabilities and Equity [Abstract]
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Liabilities, Current [Abstract]
Current liabilities:
Accounts Payable, Current
Accounts payable
Accrued Liabilities, Current
Accrued and other current liabilities
Total accrued and other current liabilities
Accrued clinical site costs.
Accrued clinical site costs
Accrued clinical site costs
Convertible notes payable accrued interest.
Convertible Notes Payable Accrued Interest
Convertible note payable and accrued interest
Derivative Liability, Current
Warrant liabilities
Liabilities, Current
Total current liabilities
Liabilities
Total liabilities
Commitments and Contingencies
Commitments and Contingencies (Note 8)
Stockholders' deficit:
Preferred Stock, Value, Issued
Preferred stock, value
Common Stock, Value, Issued
Common stock, $0.001 par value, 500,000,000 shares authorized; 9,772,672 and 8,391,940 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Additional Paid in Capital
Additional paid-in capital
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Stockholders' Equity Attributable to Parent
Ending balance
Beginning balance
Total stockholders' deficit
Liabilities and Equity
Total liabilities and stockholders' deficit
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Preferred Stock, Shares Issued
Preferred stock, shares issued
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding
Common Stock, Par or Stated Value Per Share
Common stock, par value
Common Stock, Shares Authorized
Common stock, shares authorized
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Outstanding
Common stock, shares outstanding
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Operating Expenses [Abstract]
Operating expense:
Research and Development Expense
Research and development
General and Administrative Expense
General and administrative
Operating Expenses
Total operating expenses
Operating Income (Loss)
Loss from operations
Nonoperating Income (Expense) [Abstract]
Other (income) expense:
Interest Income, Other
Interest income
Interest Expense
Interest expense
The increase (decrease) in fair value of convertible debt during the period.
Increase (Decrease) In Fair Value Of Convertible Debt
Change in fair value of convertible note payable
Change in fair value of convertible promissory note
Fair value adjustment through earnings
Derivative, Gain (Loss) on Derivative, Net
Change in fair value of warrant liabilities
Change in fair value of warrant liability
Nonoperating Income (Expense)
Total other expense
Net loss
Net loss
The portion of profit or loss for the period, net of income taxes, which is attributable to common stockholders.
Net loss attributable to common stockholders
Comprehensive (income) loss:
Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, Reclassification Adjustment from AOCI for Derecognition, after Tax
Change in fair value of convertible note attributed to credit risk
Change in fair value of convertible note attributed to credit risk
Other Comprehensive Income (Loss), Net of Tax
Other comprehensive income
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Comprehensive loss
Earnings Per Share [Abstract]
Net loss per share:
Earnings Per Share, Basic
Basic
Earnings Per Share, Diluted
Diluted
Weighted average common shares outstanding:
Weighted Average Number of Shares Outstanding, Basic
Basic
Weighted Average Number of Shares Outstanding, Diluted
Diluted
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY
Equity Components [Axis]
Equity Component [Domain]
Preferred Stock [Member]
Preferred Stock
Additional Paid-in Capital
Accumulated Deficit
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income Loss
Series A
Sale of Stock [Axis]
Sale of Stock [Domain]
Represents information pertaining to At the market offering.
At The Market Offering [Member]
At-the-market offering
Shares, Outstanding
Ending balance, shares
Beginning balance, shares
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Stock-based compensation
Value of preferred stock shares converted into common stock.
Conversion Of Preferred Stock Into Common Stock, Value
Conversion of Series A preferred stock into common stock
Number of preferred stock shares converted into common stock.
Conversion Of Preferred Stock Into Common Stock, Shares
Conversion of Series A preferred stock into common stock, shares
Stock Issued During Period, Value, New Issues
Common stock issued
At-the-market "ATM" offering, net of offering costs $48
Stock Issued During Period, Shares, New Issues
Number of shares issued
At-the-market "ATM" offering, net of offering costs $48, shares
Equity impact of the value of common stock and warrants issued during the period.
Common Stock And Warrants Issued, Value, New Issues
Common stock and warrants issued, net of issuance costs
Number of common stock and warrants issued during the period.
Common Stock And Warrants Issued, Shares, New Issues
Common stock and warrants issued, net of issuance costs, shares
Represents the value of common stock and warrants issued in a private placement, net of issuance costs.
Common Stock And Warrants Issued In Private Placement, Net Of Issuance Costs
Common stock and warrants issued in private placement (270,000 common stock shares to be issued)
Represents the number of shares of common stock issued in a private placement of common stock and warrants.
Common Stock And Warrants Issued In Private Placement, Number Of Shares
Common stock and warrants issued in private placement (270,000 common stock shares to be issued) (in shares)
Shares of common stock sold
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Vesting of restricted stock awards
Stock Issued During Period, Value, Conversion of Convertible Securities
Issuance of common stock as principal and interest repayment for convertible notes
Shares issued as repayment of principal and interest for convertible note
Stock Issued During Period, Shares, Conversion of Convertible Securities
Shares issued as repayment of principal and interest for convertible note (in shares)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
At-the-market offering, net of offering cost,
Underwriting discounts and commissions
Represents the issuance costs associated with a sale of stock and warrants.
Sale Of Stock And Warrants, Issuance Costs
Preferred, common stock and warrants issued, issuance costs
Number of shares to be issued.
Number Of Shares To Be Issued
Common stock shares to be issued
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Net Cash Provided by (Used in) Operating Activities [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Depreciation expense
Share-based Payment Arrangement, Noncash Expense
Stock-based compensation
Fair Value Adjustment of Warrants
Change in fair value of warrant liabilities
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expense and other assets
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Accrued expense and other liabilities
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
CASH FLOWS FROM INVESTING ACTIVITIES
Payments to Acquire Productive Assets
Purchase of computer equipment
Net Cash Provided by (Used in) Investing Activities
Net cash used in investing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
CASH FLOWS FROM FINANCING ACTIVITIES
The cash outflow for a repayment of a convertible note.
Repayments of convertible note
Repayment of convertible note
The amount of cash inflow associated with issuance of common stock and warrants, net of issuance costs.
Proceeds From Issuance Of Common Stock And Warrants, Net Of Issuance Costs
Proceeds from issuance of common stock and warrants, net of issuance costs
Represents net proceeds (payments) for issuance of common stock and warrants in a private placement, net of issuance costs.
Net Proceeds From (Payments For) Issuance Of Common Stock And Warrants In Private Placement, Net Of Issuance Costs
Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Net decrease in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash and cash equivalents at end of period
Cash and cash equivalents at beginning of period
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities
Cash paid for interest
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Non-cash investing and financing activities
Issuance of Common Stock Warrants as Offering Costs
Issuance of Common Stock Warrants as Offering Costs
Issuance of common stock warrants as offering costs
Conversion of Stock, Amount Converted
Conversion of Series A preferred stock into common stock
The value of warrants issued under non-cash financing activity.
Warrants Issued
Warrants issued pursuant to the Alvogen Agreement amendment
Organization
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Organization
Going Concern [Abstract]
Going Concern [Abstract]
Going Concern
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Prepaid Expenses and Other Current Assets
The entire disclosure of prepaid expenses and other current assets.
Disclosure of Prepaid Expenses and Other Current Assets [Text Block]
Prepaid Expenses and Other Current Assets
Accrued and Other Current Liabilities
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
Accrued and Other Current Liabilities
No definition available.
Alvogen Licensing Agreement
The disclosure of Alvogen licensing agreement.
Alvogen Licensing Agreement [Text Block]
Alvogen Licensing Agreement
Debt.
Debt Disclosure [Text Block]
Debt
Commitments and Contingencies.
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Equity
Stockholders' Equity Note Disclosure [Text Block]
Equity
Stock-Based Compensation
Share-based Payment Arrangement [Text Block]
Stock-Based Compensation
Fair Value Measurements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]
Fair Value Measurements
Income Taxes
Income Tax Disclosure [Text Block]
Income Taxes
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Subsequent Events
Subsequent Events [Text Block]
Subsequent Events
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation and Principles of Consolidation
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Risk And Uncertainties Policy [Text Block]
Risk And Uncertainties Policy [Text Block]
Certain Risks and Uncertainties
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk and Off-Balance Sheet Risk
Revenue [Policy Text Block]
Revenue Recognition
Research and Development Expense, Policy [Policy Text Block]
Research and Development Costs
Debt, Policy [Policy Text Block]
Note Payable
Share-based Payment Arrangement [Policy Text Block]
Stock-Based Compensation
information expressed about Warrant policies
Warrant Liability [Policy Text Block]
Warrants
information expressed about Modification of Warrants.
Modification Of Warrants [Policy Text Block]
Modification of warrants
Disclosure of accounting policy for preferred stock.
Preferred Stock Policy [Policy Text Block]
Preferred Stock
Income Tax, Policy [Policy Text Block]
Income Taxes
Earnings Per Share, Policy [Policy Text Block]
Loss Per Share
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
Disclosure of accounting policy non-cancellable contracts.
Non-cancellable Contracts
Non-cancellable contracts
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Outstanding Shares of Common Stock Equivalents Excluded From Diluted Net Loss Per Share
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
Schedule of prepaid expenses and other current assets
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Schedule of Accrued and other current liabilities
Tabular disclosure of the milestone payment related to license agreement.
Schedule Of Milestone Payment Related To License Agreement [Table Text Block]
Schedule of milestone payment related to license agreement
Schedule of Stock by Class [Table]
Class of Stock [Line Items]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Summary of activity for warrants
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Option, Activity [Table Text Block]
Schedule of stock option activity
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
Schedule of restricted stock activity
Share-based Payment Arrangement, Cost by Plan [Table Text Block]
Summary of recognition of stock-based compensation
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Liability Class [Axis]
Fair Value by Liability Class [Domain]
Convertible Notes Payable [Member]
Convertible notes payable
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Domain]
Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Summary of fair value hierarchy
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Schedule of measure the convertible note liability
Convertible Debt [Table Text Block]
Summary of Convertible note payable
No definition available.
Schedule Of Warrant Liability Valuation Assumptions Table Text Block
Schedule of significant unobservable inputs
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of reconciliation of liabilities
Schedule of Related Party Transactions, by Related Party [Table]
Product and Service [Axis]
Product and Service [Axis]
Product and Service [Domain]
Product and Service [Domain]
Represents the information pertaining to therapeutic product, NRX-101.
Therapeutic Product, NRX-101 [Member]
NRX-101
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Represents the information pertaining to Exclusive, Global - Development, Supply, Marketing & License Agreement.
Exclusive, Global - Development, Supply, Marketing & License Agreement [Member]
License Agreement
Counterparty Name [Axis]
Counterparty Name [Axis]
Counterparty Name [Domain]
Counterparty Name [Domain]
Represents the information pertaining to Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.
Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd [Member]
Alvogen
Related Party Transaction [Line Items]
Commitments and Contingencies
Term of license agreement from the first commercial sale of Product.
License Agreement, Initial Term
Initial term
Renewal term of license agreement upon request made prior to the expiration of such initial term.
License Agreement, Renewal Term
Renewal term
Schedule of Long-term Debt Instruments [Table]
Securities Purchase Agreement March 8, 2023.
Securities Purchase Agreement March 8, 2023 [Member]
Securities Purchase Agreement
Represents information related to the Alvogen Milestone Advance.
Alvogen Milestone Advance [Member]
Represents information related to Proceeds received in April.
Proceeds received in April [Member]
Represents information related to Steeterville LLC.
Streeterville LLC [Member]
Debt Instrument [Line Items]
Cash
Cash and cash equivalents
Class of Warrant or Right, Exercise Price of Warrants or Rights
Outstanding at the end (in dollars per share)
Outstanding at the beginning (in dollars per share)
Warrants, exercise price per share
Warrants and Rights Outstanding, Term
Warrants expiration term
Proceeds from Issuance of Common Stock
Proceeds from issuance of Common stock, net of transaction costs
Aggregate gross proceeds from the Offering
Debt Instrument, Term
Maturity term
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Number of shares per warrant
Share Price
Stock price on valuation date
Share price
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Restricted stock awards
Business Acquisition [Axis]
Business Acquisition, Acquiree [Domain]
Represents the information pertaining to merger agreement with merger sub and NeuroRx.
Merger agreement
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Stockholders' Equity Note, Stock Split, Conversion Ratio
Exchange Ratio
Reduction in the number of shares during the period as a result of a reverse stock split.
Fractional Stock Issued During Period, Shares, Reverse Stock Splits
Fractional Shares issued, Reverse Stock Split
Amount of clinical development expenses paid in advance.
Prepaid Clinical Development Expenses
Prepaid clinical development costs
Prepaid Insurance
Prepaid insurance
Other Prepaid Expense, Current
Other prepaid expense
Other Assets, Current
Other current assets
Accounts and Other Receivables, Net, Current
Other current receivables
Accrued Liabilities and Other Liabilities [Abstract]
Accrued and other current liabilities:
Accrued Professional Fees, Current
Professional services
Accrued Research And Development Expenses Current
Accrued Research And Development Expenses Current
Accrued research and development expense
Accrued Employee Benefits, Current
Accrued employee costs
Amount of other expenses incurred but not yet paid , due within one year or the normal operating cycle, if longer.
Other Accrued Expenses, Current
Other accrued expense
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Alvogen Licensing Agreement.
Period of prior written notice for terminate at any time after the First Milestone Payment has been made.
License Agreement, Threshold Period for Termination upon Prior Written Notice After First Milestone Payment
Period for prior written notice on termination
The accelerated amount under the first initial payment amount to be received.
Initial Cash Payment To Be Received, Accelerated Amount
Accelerated Amount
The remaining amount under the first initial payment amount to be received.
Initial Cash Payment To Be Received, Remaining Amount
First initial payment
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Warrants exercised
Customer Refund Liability, Current
Refund liability
Number of business days for payment of equitable royalty in case of reversion license.
License Agreement, Minimum Period for Equitable Royalty Payable In Case of Reversion License
Equity royalty payable period in case of reversion license
Initial cash payment to be received.
Initial Cash Payment to be Received
First milestone payment to be received
Second milestone payments receivable.
Second Milestone Payments Receivable
Second milestone payment receivable
Maximum bonus milestone payments receivable.
Maximum Bonus Milestone Payments Receivable
Maximum bonus milestone payment receivable
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Information pertaining to the 9% Redeemable Promissory Note.
Promissory Note 9% Redeemable [Member]
Scenario [Axis]
Scenario [Domain]
Represents the second amendment the company entered into on July 7 regarding the 9% note.
Amendment Two [Member]
Represents the third amendment the company entered into on february 9, 2024 regarding the 9% note.
Amendment Three [Member]
Represents trigger events that indicate the 9% note is in default.
Default Trigger Events [Member]
Debt Instrument, Interest Rate, Stated Percentage
Interest rate percentage
Debt Instrument, Face Amount
Amount of original issue discount of debt instrument.
Debt Instrument, Original Issue Discount
Original issue discount
Proceeds from Notes Payable
Net proceeds from issuance of notes
Amount payable on prepayment of debt represented as a percentage of the principal, interest and fees owed as of the prepayment date.
Debt Instrument, Prepayment, Amount Payable As A Percentage Of Principal, Interest And Fees Owed
Amount payable on prepayment of notes as a percentage of the principal, interest, and fees owed
Maximum outstanding balance of the debt instrument that can be redeemed by the holder per month.
Debt Instrument, Maximum Outstanding Balance That Can Be Redeemed By The Holder Per Month
Maximum outstanding balance of the Note that can be redeemed by the holder per month
Percentage of premium payable on amount redeemed if the debt instrument is redeemed in cash.
Debt Instrument, Redemption, Percentage Of Premium Payable On Amount Redeemed If Redeemed In Cash
Percentage of premium payable on amount redeemed if the notes are redeemed in cash
Redemption Conversion Price of the debt instrument, as a percentage of average lowest daily volume weighted average prices per share of the company.
Debt Instrument, Redemption Conversion Price As A Percentage Of Average Lowest Daily Volume Weighted Average Prices Per Share
Redemption Conversion Price as a percentage of average lowest daily volume weighted average prices per share of the common stock
Number of lowest daily volume weighted average prices per share of the company considered for determination of Redemption Conversion Price of the debt instrument.
Debt Instrument, Redemption Conversion Price, Number Of Lowest Daily Volume Weighted Average Prices Per Share Considered
Redemption Conversion Price, Number of lowest daily volume weighted average prices per share of the common stock considered
Number of trading days over which the average of the lowest daily volume weighted average prices per share of the company is considered for determination of Redemption Conversion Price of the debt instrument.
Debt Instrument, Redemption Conversion Price, Number Of Trading Days Considered
Redemption Conversion Price, Number of trading days considered
Minimum percentage of daily dollar trading volume of the common stock considered to trigger redemption of debt instrument.
Debt Instrument, Redemption Trigger, Minimum Percentage Of Daily Dollar Trading Volume Of Common Stock Considered
Minimum percentage of daily dollar trading volume of the common stock considered to trigger redemption of Notes
Number of previous trading days over which the median daily dollar trading volume is considered to trigger redemption of Notes
Debt Instrument, Redemption Trigger, Number Of Previous Trading Days Over Which The Median Daily Dollar Trading Volume Is Considered
Number of previous trading days over which the median daily dollar trading volume is considered to trigger redemption of Notes
Minimum percentage by which the closing trade price exceeds the Nasdaq Minimum Price, considered to trigger the redemption of debt instrument.
Debt Instrument, Redemption Trigger, Minimum Percentage By Which The Closing Trade Price Exceeds The Nasdaq Minimum Price, Considered
Minimum percentage by which the closing trade price exceeds the Nasdaq Minimum Price, considered to trigger redemption of Notes
Number of following trading days over which the closing trade price is consider to trigger redemption of debt instrument.
Debt Instrument, Redemption Trigger, Number Of Following Trading Days Over Which The Closing Trade Price Is Considered
Number of following trading days over which the closing trade price is considered to trigger redemption of Notes
Monthly redemption amount of the debt instrument.
Debt Instrument, Monthly Redemption Amount
Monthly redemption amount
Debt Instrument, Convertible, Threshold Trading Days
Number of trading days
Represents information pertaining to maximum percentage of number of shares of Common Stock outstanding.
Maximum Percentage Of Common Stock Outstanding
Maximum percentage of Common Stock outstanding
Represents the amount agreed to pay in cash to amend the redemption provisions.
Debt Instrument, Amount Agreed To Pay In Cash To Amend The Redemption Provisions
Amount agreed to pay in cash to amend the redemption provisions
Amount of minimum payment per month on or before the last day of each month in relation to debt instrument.
Debt Instrument, Minimum Monthly Payments
Minimum Payment
Represents the maximum monthly redemption amount per month.
Debt Instrument, Maximum Monthly Redemption Amount per Month
Maximum monthly redemption amount per month
Debt Instrument, Unamortized Discount
Debt discount
Amount of the required periodic payments applied to interest paid in cash.
Debt Instrument, Periodic Payment, Interest Paid in Cash
Cash interest repayments made
The amount of cash outflow for payment of redemption premium.
Payment Of Redemption Premium
Payment of redemption premium
Amount of the required periodic payments applied to interest paid in stock.
Debt Instrument, Periodic Payment, Interest Paid From Issuance of Stock
Shares of common stock issued as interest repayment
Amount of the required periodic payments applied to principal paid in cash.
Debt Instrument, Periodic Payment, Principal Paid in Cash
Cash principal repayments made
Amount of the required periodic payments applied to principal paid in stock.
Debt Instrument, Periodic Payment, Principal Paid From Issuance of Stock
Shares of common stock issued as principal repayment
Convertible Debt
Convertible debt
Carrying value of the Note before current period change in fair value
Commitments and Contingencies [Table]
Commitments and Contingencies [Table]
Commitments and Contingencies [Table]
Represents information pertaining to Sarah Herzog Memorial Hospital License Agreement.
Sarah Herzog Memorial Hospital License Agreement [Member]
SHMH license agreement
Represents the scenario pertaining to end of phase I clinical trials of licensed product.
End Of Phase I Clinical Trials Of Licensed Product [Member]
End of Phase I Clinical Trials of Licensed Product
Represents the scenario pertaining to end of phase II clinical trials of licensed product.
End Of Phase II Clinical Trials Of Licensed Product [Member]
End Of Phase II Clinical Trials Of Licensed Product
Represents the scenario pertaining to end of phase III clinical trials of licensed product.
End Of Phase III Clinical Trials Of Licensed Product [Member]
End of Phase III Clinical Trials of Licensed Product
Represents the scenario pertaining to first commercial sale of licensed product in US.
First Commercial Sale Of Licensed Product In US [Member]
First Commercial Sale of Licensed Product in U.S.
Represents the scenario pertaining to first commercial sale of licensed product in Europe.
First Commercial Sale Of Licensed Product In Europe [Member]
First Commercial Sale of Licensed Product in Europe
Represents the scenario pertaining to annual revenues reach 100,000,000.
Annual Revenues Reach 100,000,000 [Member]
Annual Revenues Reach $100,000,000
Commitments and Contingencies [Line Items]
Commitments and Contingencies [Line Items]
Commitments and Contingencies
The amount of milestone payments payable under the arrangement.
Milestone Payments, Payable
Milestone payments
Amount of milestone payments annual revenues reach.
Milestone Payments Annual Revenues Reach
Milestone payments annual revenues reach
Percentage Of certain circumstances.
Percentage Of Certain Circumstances
Percentage Of certain circumstances
License [Member]
License
Percentage of revenue from sale of product.
Percentage Of Revenue From Sale Of Product Not Covered By Valid Claim
Percentage of revenue from sale of product not covered by valid claim
Percentage of revenue from sale of product.
Percentage Of Revenue From Sale Of Product Covered By Valid Claim
Percentage of revenue from sale of product covered by valid claim
Percentage of payment received from sub license in sale.
Percentage Of Payment Received From Sub License In Sale
Percentage of payment received from sub license in sale
Amount of payments for fixed annual maintenance fee.
Payments For Fixed Annual Maintenance Fee
Payments for fixed annual maintenance fee
Amount of payments for fixed annual maintenance fee thereafter.
Payments For Fixed Annual Maintenance Fee Thereafter
Payments for fixed annual maintenance fee thereafter
Represents information pertaining to Apkarian Technologies Exclusive License Agreement.
Apkarian Technologies Exclusive License Agreement [Member]
Apkarian Technologies
Related Party [Axis]
Related Party [Domain]
Nonrelated Party [Member]
Nonrelated Party
Contractual Obligation
Contractual obligation
Amount of worth expenses relating to the relicense of the patent.
Worth Of Expenses Relating To License Of Patent
Worth expenses relating to the relicense of the patent
Operating Cost and Expense, Related Party, Type [Extensible Enumeration]
Statistical Measurement [Axis]
Statistical Measurement [Domain]
Maximum
Maximum
Operating Lease, Expense
Relief Therapeutics Collaboration Agreement.
Relief Therapeutics Collaboration Agreement [Member]
Relief Therapeutics Collaboration Agreement
Litigation Status [Axis]
Litigation Status [Domain]
Relief Therapeutics Lawsuit [Member]
Represents information pertaining to Relief Therapeutics lawsuit.
Relief Therapeutics Lawsuit
Represents information pertaining to Relief Therapeutics Holdings, AG.
Relief Therapeutics Holdings, AG
The amount of milestone payments receivable under collaborative arrangement.
Collaborative Arrangement, Milestone Payments Receivable
Milestone payments receivable
The amount of royalty payments receivable under collaborative arrangement.
Collaborative Arrangement, Royalty Payments Receivable
Royalty payments receivable
The threshold amount of indemnity claims exceeding which, the company is not liable to pay
Collaborative Arrangement, Threshold Liability for Indemnity Claims
Indemnity claims
he threshold amount of indemnity obligations on breach of representations and warranties, exceeding which, the company is not liable to pay.
Collaborative Arrangement, Threshold Indemnity Obligation for Breach of Representations and Warranties
Representations and Warranties
The threshold amount of indemnity obligations on breach of covenants and other agreements, exceeding which, the company is not liable to pay.
Collaborative Arrangement, Threshold Indemnity Obligation for Breach of Covenants and Other Agreements
Covenants and Other Agreements
Represent information pertaining to ATM Purchase Agreement.
ATM Purchase Agreement [Member]
ATM Purchase Agreement
Represent information pertaining to underwritten public offering.
Underwritten Public Offering [Member]
Underwritten Public Offering
Represent information pertaining to February 2024 Public Offering.
February 2024 Public Offering [Member]
February 2024 Public Offering
Represent information pertaining to February underwriting agreement.
February Underwriting Agreement [Member]
February Underwriting Agreement
Over-Allotment Option [Member]
Over-Allotment Option
Represent information pertaining to EF Hutton LLC.
EF Hutton LLC [Member]
EF Hutton LLC
Minimum
Minimum
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Represent information pertaining to Streeterville Note.
Streeterville Note [Member]
Streeterville Note
Represent information pertaining to amendment.
Amendment [Member]
Amendment
Represent information pertaining to second amendment.
Second Amendment [Member]
Second amendment
Shares Issued, Price Per Share
Purchase price
Repayments of Debt
Payments of Stock Issuance Costs
Less: transaction costs and advisory fees allocated to NRXP equity
Proceeds from Issuance of Convertible Preferred Stock
Aggregate cash purchase price
Stock Issued During Period, Shares, Reverse Stock Splits
Number of issued and outstanding common stock
Conversion of Stock, Shares Converted
Number of share converted
Sale of Stock, Price Per Share
Sale of stock per share
Percentage of premium offering price.
Percentage Of Premium Offering Price
Percentage of premium offering price
Sale of Stock, Number of Shares Issued in Transaction
Number of shares accredited investors purchased
Sale of Stock, Consideration Received on Transaction
Consideration received on transaction
Represents the purchase additional shares.
Number Of Days Option To Purchase Additional Shares
Purchase additional term
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Granted (in shares)
Number of fractional shares issued related with reserve stock split.
Number Of Fractional Shares Issued Related With Reserve Stock Split
Number of fractional shares
Number of common stock received in fractional shares.
Number Of Common Stock Received In Fractional shares
Number of receive a fractional share
Proceeds from Issuance or Sale of Equity
Proceeds from offering
Convertible Preferred Stock, Shares Issued upon Conversion
Shares issued upon conversion
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Represents the information pertaining to Substitute Warrants.
Substitute Warrants
Represents the information pertaining to stockholders of NeuroRx.
Stockholders of NeuroRx
Class of Warrant or Right, Outstanding
Outstanding at the end
Outstanding at the beginning
Number of outstanding right
Number of outstanding warrants
Class of Warrant or Right, Unissued
Warrants outstanding Unissued
Represents the information pertaining to Public Warrants.
Public Warrants
Represents the class of warrant or right exercised during the period.
Warrants Exercised During Period
Warrants exercised during period
Represents the information pertaining to Placement Warrants.
Placement Warrants
Class of Warrant or Right [Table]
Represent information pertaining to February 2024 Over-Allotment Option.
February 2024 Over Allotment Option [Member]
February 2024 Over-Allotment Option
Represent information pertaining to Alvogen licensing agreement.
Alvogen Licensing Agreement [Member]
Alvogen Licensing Agreement
Measurement Input Type [Axis]
Measurement Input Type [Domain]
Stock price on valuation date
Exercise price per share
Expected life
Volatility
Risk-free rate
Dividend yield
Measurement input using fair value of share.
Fair value of warrants
Class of Warrant or Right [Line Items]
Warrant exercisable term from date of issuance.
Warrant Exercisable Term From Date Of Issuance
Warrant exercisable term from date of issuance
Warrant maturity term from date of issuance.
Warrant Maturity Term From Date Of Issuance
Warrant maturity term from date of issuance
Warrants and Rights Outstanding, Measurement Input
Warrants and rights outstanding, measurement input
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares
Change to additional paid-in capital
Percentage of beneficial ownership limitation of post exercise.
Percentage of Beneficial Ownership Limitation of Post-Exercise
Percentage of beneficial ownership limitation of post exercise
Percentage of beneficial ownership limitation may be waived up to a maximum.
Percentage Beneficial Ownership Limitation May be Waived Up To a Maximum
Percentage of beneficial ownership limitation may be waived up to a maximum
No definition available.
Class of Warrant or Right, Number [Abstract]
Total Warrants
Represents the number of warrants or rights Issued during the period.
Class Of Warrant Or Rights Issued
Issued
Represents the number of warrants or rights expired during the period.
Class Of Warrant Or Right Expired
Expired
No definition available.
Class of Warrant or Right, Weighted Average Remaining Term [Abstract]
Weighted Average Remaining Term
Represents the weighted average remaining contractual term of warrants.
Class Of Warrant Or Right Weighted Average Remaining Contractual Term 2
Outstanding
No definition available.
Class of Warrant or Right, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price
No definition available.
Class of Warrant or Right, Aggregate Intrinsic Value [Abstract]
Aggregate Intrinsic Value
Represents the intrinsic value of class of warrant or right outstanding.
Class of Warrant or Right Outstanding Intrinsic Value
Outstanding at the end (in dollars)
Outstanding at the beginning (in dollars)
Plan Name [Axis]
Plan Name [Domain]
Two Thousand Sixteen Omnibus Plan [Member]
Two Thousand Sixteen Omnibus Plan [Member]
2016 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Number of shares authorized for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Outstanding at the end (in shares)
Outstanding at the beginning (in shares)
Options to purchase shares of common Stock
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Outstanding at the end (in dollars per share)
Outstanding at the beginning (in dollars per share)
Exercise price
Represents information pertaining to 2021 Omnibus Incentive Plan.
2021 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Number of additional shares authorized
Percentage of outstanding shares used to determine the number of additional shares authorized annually under the plan.
Option Awards Percentage Of Outstanding Shares Used To Determine Additional Shares Authorized Voting Interests Retained By Shareholders
Percentage of outstanding shares for determination of annual additional shares authorization
Increase in maximum number of shares available for grant under the share based arrangement.
Share-Based Compensation Arrangement by Share-Based Payment Award, Increase in Number of Shares Available for Grant
Increase in number of shares available for grant
Percentage of shares issued upon exercise of options granted to the share pool under the share based compensation arrangement.
Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Shares Issued Upon Exercise Of Options Granted Percentage To Share Pool
Share-based compensation arrangement by share-based payment award number of shares issued upon exercise
Represents the aggregate number of options granted to-date.
Share-Based Compensation Arrangement, Payment Award Options, Aggregate Granted
Number of shares awarded
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Number of shares available for issuance
Stock Options [Member]
Options
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Dividend yield
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Expired/Forfeited
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Options vested and exercisable (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Options vested and exercisable (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining remaining term (in years)
Weighted average remaining contractual term for option awards outstanding during the period.
Share Based Compensation Arrangement Options Outstanding, Weighted Average Remaining Contractual Term 2
Outstanding (in years)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term
Options vested and exercisable (in years)
Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]
Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]
Aggregate intrinsic value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Outstanding at the end (in dollars)
Outstanding at the beginning (in dollars)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Options vested and exercisable
Share-based Payment Arrangement, Expense
Stock-based compensation expense
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Unrecognized compensation
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Weighted-average period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Balance, beginning of period
Balance, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Shares granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Shares vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Grant date fair value, beginning of period
End of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Grant date fair value, granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Grant date fair value, vested
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period
Vesting period
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value
Equity instruments other than options, granted
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Income Statement Location [Axis]
Income Statement Location [Domain]
General and administrative
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Measurement Frequency [Axis]
Measurement Frequency [Domain]
Fair Value, Recurring [Member]
Recurring basis
Level 1
Assets, Fair Value Disclosure [Abstract]
Assets:
Cash and Cash Equivalents, Fair Value Disclosure
Money Market Account
Liabilities, Fair Value Disclosure [Abstract]
Liabilities:
Convertible Debt, Fair Value Disclosures
Fair Value of Note-Ending Balance
Fair Value of Note-Beginning Balance
Convertible note payable (Note 7)
Time to expiration
Measurement input using market interest rate.
Note market interest rate
Measurement input using equity volatility.
Equity volatility
Measurement input using volume volatility.
Volume volatility
Probability of default
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Periodic Payment, Principal
Conversions and repayments of principal and interest (shares and cash)
The increase (decrease) in fair value of accumulated other comprehensive income from convertible debt during the period.
Increase (Decrease) In Fair Value accumulated other comprehensive income
Fair value adjustment through accumulated other comprehensive loss
Convertible Debt, Current
Convertible note payable - current portion
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Balance at the end
Balance at the beginning
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Gain/Loss upon re-measurement
Income Tax Expense (Benefit)
Income tax benefits
Number of open tax audits with any taxing authority.
Number Of Open Tax Audits
Tax audits
Agreement [Axis]
Agreement [Axis]
Agreement [Domain]
Agreement [Domain]
Glytech Agreement [Member]
Glytech Agreement [Member]
Information related to the former CEO.
Former Chief Executive Officer [Member]
Former CEO
Chief Executive Officer Son [Member]
Chief Executive Officer Son [Member]
Related Party [Member]
The minimum value of equity required for the transfer of assets from related parties to the Company.
Minimum Equity Value Required For Transfer Of Assets
Minimum equity required for transfer of Excluded Technology
Number of consecutive trading days required of minimum equity met for the transfer of assets from a related party to the Company.
Minimum Equity Required For Transfer Of Assets From Related Party, Number of Consecutive Trading Days
Number of consecutive trading days
Number of trading days required of minimum equity met for the transfer of assets from a related party to the Company.
Minimum Equity Required For Transfer Of Assets From Related Party, Number of Trading Days
Number of trading days
Related Party Transaction, Amounts of Transaction
Payment to related party
Threshold aggregate liquidity of the related party.
License Agreement, Threshold Aggregate Liquidity
Threshold aggregate liquidity of the related party
The amount of consulting fee payable per month under related party transactions.
Related Party Transaction, Consulting Fee Payable Per Month
Consulting fee payable per month
The amount of performance-based annual bonus with a minimum target payable under related party transaction.
Related Party Transactions, Performance Based Annual Bonus Minimum Target
Performance based annual bonus minimum target
Number of shares shall have restrictions removed on new drug application date.
Number of Shares, Restrictions Removed on New Drug Application Date
Number of shares, restrictions removed on new drug application date
Number of shares will have restrictions removed on new drug approval date.
Number of Shares, Restrictions Removed on New Drug Approval Date
Number of shares, restrictions removed on new drug approval date
Accounts Payable
Accounts payable due to related parties
Subsequent Event [Table]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event [Member]
Represents the information pertaining to April 2024 underwritten public offering.
April 2024 Underwritten Public Offering [Member]
April 2024 Underwritten Public Offering
Represents the information pertaining to underwriters warrants.
Underwriters Warrant [Member]
Underwriters warrants
Subsequent Event [Line Items]
Loss Contingency, Damages Sought, Value
Damages sought
Amount of aggregate prospectus supplement under offering agreement.
Aggregate Prospectus Supplement Amount
Offering agreement for an aggregate
Common Stock, Capital Shares Reserved for Future Issuance
Underwritten public offering
Over-allotment option period.
Over Allotment Option Period
Over Allotment Option Period
Percentage of shares issuable upon exercise of warrants on total stock outstanding and any option shares sold.
Percentage of Shares Issuable upon Exercise of Warrants
Percentage of shares issuable
Period for exercise of warrants from the date of agreement.
Warrants and Rights Outstanding, Exercisable Term
Period for exercise of warrants
Period for expiration of warrants from the date of agreement.
Warrants and Rights Outstanding, Expiration Term
Period for expiration of warrants